GINKGO BIOWORKS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On October 19, 2022, Ginkgo Bioworks Holdings, Inc. ("Ginkgo") filed a Current Report on Form 8-K with the Securities and Exchange Commission to report the completion of its acquisition of Zymergen Inc. ("Zymergen"). Ginkgo is filing this Current Report on Form 8-K to include certain updated financial statements of Zymergen and certain updated pro forma financial information in connection with the acquisition.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired

The unaudited consolidated interim financial statements of Zymergen as of and for the quarterly period ended September 30, 2022 are filed as Exhibit 99.1 attached hereto and incorporated herein by reference.

(b)

The unaudited pro forma condensed combined balance sheet as of September 30, 2022 and the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2022 and the year ended December 31, 2021 are filed as Exhibit 99.2 attached hereto and incorporated herein by reference.

(d) Exhibits.

Exhibit Number        Description

99.1                    Unaudited Consolidated Interim Financial Statements for
                      Zymergen Inc. as of and for the quarterly period ended
                      September 30, 2022.

99.2                    Unaudited Pro Forma Condensed Combined Balance Sheet as of
                      September 30, 2022 and the Unaudited Pro Forma Condensed
                      Combined Statements of Operations for the nine months ended
                      September 30, 2022 and the year ended December 31, 2021.

104                   Cover Page Interactive Data File (embedded within the Inline
                      XBRL).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses